Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-α and interleukin-1β by peripheral blood monocytes in the acute phase of Kawasaki disease
- 49 Downloads
In order to study the in vitro effects of intact immunoglobulin (Ig) and gamma-interferon (INF-γ) in patients with Kawasaki disease, the production of tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) was measured in peripheral blood monocytes (PBM) both before and after intravenous immunoglobulin (IVIG) therapy. Spontaneous production of TNF-α and IL-1β both before and after IVIG therapy was significantly higher than in healthy controls. Intact Ig enhanced in vitro the production of TNF-α and IL-1β both before and after IVIG therapy approximately 3–4 times as compared to the spontaneous production. INF-γ did not affect the production of the two cytokines. Ig enhanced IL-1β mRNA expression in PBM of KD by 3–8 times more than that of spontaneous production.
These results suggest that: (1) the mechanism of action of IVIG therapy in KD is not to cut down the production of inflammatory cytokines such as TNF-α and IL-1β andf that (2) the changes of these cytokine levels may be related to the clinical effectiveness of high dose IVIG.
Key wordsKawasaki disease Immunoglobulin therapy TNF-α IL-1β Macrophages/monocytes
intravenous imm unoglobulin
peripheral blood monocytes
tumour necrosis factor-α
Unable to display preview. Download preview PDF.
- 7.Furusho K, Kamiya T, Nakano H, Kiosawa N, Shinomyia K, Hayashida T, et al (1984) High dose intravenous gammaglobulin for Kawasaki disease. Lancet II:1055–1058Google Scholar
- 9.Harada K, Yamaguchi H, Hase N, Sato T, Asai T, Tatara K, et al (1988) Intravenous gammaglobulin treatment in Kawasaki disease. Presented at the Third International Kawasaki Disease Symposium, Tokyo, Japan, Proceedings, pp 314–317Google Scholar
- 11.Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observation of 50 cases. Jpn J Allergol 16:178–222Google Scholar
- 14.Leung DYM, Cotran RS, Kurt-Jomes E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawsaki disease. Lancet II:1298–1302Google Scholar
- 20.Okuni M, Harada K, Yamaguchi H, Yanagawa H, Sonobe T, Kawasaki T (1987) Intravenous Gammaglobulin therapy in Kawasaki disease: trial of low-dose gamma globulin. In: Shulman ST (ed) Kawasaki disease. Alan R Liss. New York, pp 433–439Google Scholar
- 21.Pål Aukrust, Stig S. Frøland, Nina-Beate Liabakk, Fredrik Müller, Ingvild Nordøy, Charlotte Haug, Terje Espevik (1994) Release of cytokines, soluble cytokine receptors, and interleukine-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136–2143PubMedGoogle Scholar
- 22.Research Committee on Kawasaki Disease (1984) Report of Subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesion in Kawasaki disease. Tokyo, Japan, Ministry of Health and Welfare, pp 55–66Google Scholar
- 27.Shulman ST (1989) IVGG therapy in Kawsaki disease: mechanism of action. Clin Immunol Immunopathol 53:141–146Google Scholar
- 28.Suzuki H, Iizuka T, Uemura S, Koike M, Maeda J (1988) The pathophysiological significance of serum tumor necrosis factor in Kawasaki disease. Presented at the Third International Kawasaki Disease Symposium, Tokyo, Japan, Proceedings, pp 117–119Google Scholar